Response to: Correspondence on ‘Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer-a real-world, retrospective bicenter cohort study’ by Wang - Egbert F Smit; Willemijn S M E Theelen; Michiel M Smeenk; Vincent van der Noort; Hanieh Abedian Kalkhoran; Jeroen J M A Hendrikx (Journal for ImmunoTherapy of Cancer)